Medical cycle times are often long and painful, but they realize a significant payday when a new technology emerges. In the United States, medical OEMs strive to develop scientific breakthroughs that first receive 510 Federal Drug Administration clearance in order to market and start a revenue stream. Since this process can take one to two years, JLM concentrates its efforts with European OEMs (with revenue of $50M+) that want to enter the US market. In these cases, we obtain a license agreement with an OEM that has an established global distribution channel and financial resources. In the first stage of creating a new product, we focus on animal healthcare-veterinary markets, which allows the company to build revenue while waiting for 510 FDA clearance. By running the business in parallel with the clearance cycle, the revenue made during the waiting period can be used later to expand the human sector applications once all approvals are in place.
company under agreement:
MedTec Medizintechnik GmbH
Sportparkstr. 935578 Wetzlar, Germany www.mbst.de Biophysical Stimulation -Digital Therapeutics The Next Trillion Dollar Market By Disrupting Healthcare
JLM is the exclusive-marketing agent for MedTec Medizintechnik GmbH for the US market. The target focus is medical OEMs to license the technology on exclusive bases per selected markets. Alternatively have universal medical device to treat 10+ illnesses
The technology works for the same reason as the MRI technology works. The image giving technology is called MRI and we call our technology MRT (T for Therapy). In both technologies the resonance phenomenon is used. Below is file “Technology active principle” to see what is common and what is different subject the MRI and MRT technology. The patented MBST®- therapy from Germany provides body cells (in humans and animals) with new energy through highly specified treatment devices that aim at the particular damaged tissue. Thereby, cell metabolism is reactivated and regeneration is stimulated. Hence, pain will be significantly reduced on a long term basis and mobility will be regained. This treatment is proven out successfully with over 280,000 patients within the last 18 years.
The medical device is full body basically a chair- bed platform that incorporates MRI technology. MedTec had 5- 7 different machine and can developed one machine that will cover 10 + areas . Each illness has specific program ( a selected frequency ) but all use the same medical device. Every machine has a control box which selects the frequency , pricing etc . Apple respond prior was to make one product for a target market and be the best. This is dysfunctional human cell tissue and bring back to normal "across the board “ meaning effective for entire body from head to toe. Today MBST is proven out in arthritis , orthopedic and osteoporosis but done clinical studies in dermatology for hair growth and skin rejuvenation clinical study was limited but enough sign a LOI with Cynosure now merge with Hologic. A liver clinical study for cell tissue was impressive and also moving forward. Other partners which developed electronic stimulation technology can incorporate with MedTec. Medical devices firms are design as stand alone and incorporate in MedTec universal medical device. Thus low risk for both parties . MedTec can include 10 verticals which includes arthritis , orthopedic , osteoporosis , dermatology ( hair growth ),liver, urology - erectile dysfunction , neurosciences ( depression ), diabetes two, audiology ( regain hearing lost ) and ) ophthalmology ( improve eye sight ) . Most are CE mark and a few are FDA approved.
The three core areas:
1) ORTHOPEDICS MARKET
Diseases of the large and small joints of limb, spine and intervertebral discs
All types of joints, large or small knees, hips, feet, elbow etc
Damage to the intervertebral discs not obligatory to surgery
Sport- and accidental injuries, degenerative diseases of tendons and connective tissue
After injuries with cartilage damage
After operative cartilage cell transplantation as well as after smoothing of the cartilage surface
Post Surgery for implants typically can speed recovery for knees by three months with average of four MBST treatments
Best alternative treatment if select not to have artificial implant surgery for knees or hips
Injury recovery time world's fastest
Updated full body for MBST treatments available ( used today for osteroporsosis )
New images how the device looks like:
Full bed which looks like a Tornado seat
For positioning the patient, the bed is vertically aligned with 25° nod
Then patient will be moved to horizontal position
2 applicators are positioned around head and shoulder area
Another 2 applicators are positioned around leg and foot area
The applicators are slidable to one big, full body treatment area without black (treatment) hole
The device has 12 major indications to be treated, organs ( liver ) and soft parts most known indications osteoarthritis, osteoporosis, muscles, ligaments, tendons , neuronscience (depression ) and dermatology ( hair growth & skin rejuvenation )
Device production takes 5 days or less ( ballpark )
MedTec is licensing the technology per vertical market and a universal and preference is one firm for global exclusive rights for universal medical device . Sub license to partners for selected vertical market . As example dermatology joint venture with a firm Cynosure / Hologic
Meeting with potential Fortune 500 firms to receive a Letter of Intent for 10 +
Dermatology and Animal Healthcare arthritis ( pet care ) is strong review with market leaders
Venture Capital for Health Clinics using MedTec MBST treatments
MBST treatments the target focus for the last 18 years has been orthopedic an alternative treatment then having knnes or hip implants. Today revenue over $40 billion for recieving surgery and statically only half the patients recieve surgery. Over 200,000 treatments for the last 18 years in 30 countries ( CE Mark )
Scientific evaluation of the MBST Magnetic Resonance Technology regarding the therapeutic potential and proof of clinical efficacy
The therapeutic nuclear magnetic resonance changes the balance in intracellular calcium and reduces the interleukin-1β induced increase of NF-κB activity in chondrocytes
2) Arthritis covering hand and knees
over 50,000 treatments
If you ever want to shake up pharma market then go after arthritis the cash cow for top three that brings in $40 Billion which is for humans even pet care is estimated over $5 billion “Guarding Big Pharma ’s Crown Jewel” written up in Bloomberg https://www.bloomberg.com/news/articles/2017-09-07/this-shield-of-patents-protects-the-world-s-best-selling-drug The article mentions pharma is in legal battle with AbbVie Humira related to new patents for arthritis. MedTec MBST Treatments aims at the cure with 80% success rate with lasting effects at least two -four years . A digital therapeutics / electronic medicine by electronic stimulation treatment for an hour once a day and needs to be continuous for seven days. A medical device with programable chip cards can cure arthritis by therapy treatment and not compete against pharma. MBST has over 50,000 treatments for arthritis ( humans ) in 30 countries in Europe over the last 18 years and the majority in Germany.
MedTec MBST Treatments Regeneration Cell Tissue
CIRCADIAN RHYTHM AND OSTEOARTHRITIS - AS WINNER OF NOBEL PRIZE IN MEDICINE 2017
The Nobel Assembly at Karolinska Institute has today decided to award the 2017 Nobel Prize in Physiology or Medicine jointly to Jeffrey C. Hall, Michael Rosbash and Michael W. Young for their discoveries of molecular mechanisms controlling the circadian rhythm. This study was on targeting the cause of arthritis which won Nobel Prize in 2017
According to the latest scientific discoveries of Dr. Egg from the University in Innsbruck are that MBST corrects misaligned circadian clocks in cells. MBST is the only technology currently available worldwide which causes this correction. Also very important: The MBST-process of the correction of misaligned cells is patent protected!! MedTec study is for the treatment of the “cause” for arthritis with a success rate over 80%. Also written in two journals - Arthritis Research, UK & - Journal of clinic Investigation
According to a study, described in the,Journal of Clinical Investigation“ (UK) and further scientific publications, a circadian rhythm disruption is a risk factor for joint diseases such as Osteoarthritis.
Arthritis, could the blame be of the "bailed" biological clock?
With years the rhythms regulating the activity of cartilage cells change and favor the degeneration of joints: the possibility of new treatments
Osteoarthritis usually begins to show itself when you are no longer young.According to a study recently published on the Journal of Clinical Investigation , however, the blame could be above all the biological clock that regulates the activity of cartilage cells: with the go of the years it "sballa" and, by modifying cellular equilibrium, contributes wear on the joints.
Organic clock that ages
The link between biological clock and osteoarthritis is confirmed by further data obtained by Meng on topolines: the researcher has shown that reverse light / dark cycle, simulating what happens with shift work or in case of extreme ice, disrupts circadian rhythms and above all increases the likelihood of osteoarthritis. "The goal now is to identify drugs that can affect the biological clock to reset it: some researchers are already engaging in this for other pathologies, but arthrosis could be cured or prevented,” says Meng. There are also other approaches that are simpler and handy to try and keep the biological clock as good as possible: eating and doing regular exercise, for example, is a good way to keep up the right pace. All those who suffer from arthritis know that at some times of the day the pains are felt more, our data indicates that there is a biological explanation for this: intervening with symptomatic therapies at the right time could be of great help, once the precise trend of the biological rhythm of the cartilage cells has been identified.”
The technology works for the same reason as the MRI technology works. The image giving technology is called MRI and we call our technology MRT (T for Therapy). In both technologies the resonance phenomenon is used. Below is file “Technology active principle” to see what is common and what is different subject the MRI and MRT technology.
2.5) VETERINARY MARKET (ANIMAL HEALTHCARE —TREATMENT FOR ARTHRITIS)
5 MBST animal treatment devices at universities.
3 devices at the University of Munich (horses and small animals)
1 device at the University of Hannover (small animals, study and dissertation)
1 device at the University of Vienna (small animals)
20 vets private practice in Germany can supply references
Causal and Pain-Free: Cell Regeneration Made in Germany as a Treatment Innovation for Veterinary Medicine
After 16 years of experience in magnetic resonance treatment (MRT) technology in human medicine, the patented MBST®-MagneticResonanceTreatment has now been extended to veterinary medicine. MBST®-Veterinary, as the product is named, is a conservative therapy which is based on MRI technology – the currently best and most precise method of diagnostic analysis. With a unique success rate of more than 80% in over 260,000 patients in human medicine and international study results that are unmatched, the new MBST®-Veterinary can also help in numerous orthopedic indications in horses and companion dogs.
It is a non-invasive method that produces causal regeneration of osteoarthritis, metabolic diseases of bones, sports and accident injuries. With the unique and globally patented high-tech therapy, the regeneration ability of cells is reactivated. Body cells need a certain level of energy to be able to perform cell metabolism and cell division. Damaged cells don’t have enough energy. The patented MBST®-Veterinary therapy from Germany provides these cells with new energy through highly specified treatment devices that aim at the particular damaged tissue. Thereby, cell metabolism is reactivated and regeneration is stimulated. Hence, pain will be significantly reduced on a long term basis and mobility will be regained. More than 100 international expert publications, of which most are scientific studies, prove the effectiveness of the treatment. All new scientific results are implemented promptly into the treatment software.
Regeneration for Cartilage and Bone Damage in Veterinary Medicine
Movement is essential for horses, whether racehorse, dressage horse or breeding stallion. Causal therapies that relieve pain non-invasively and long-term, and medicate the cause of the disease effectively are now available thanks to MBST®-Veterinary. MBST® can treat osteoarthritis, injuries of bones, tendons or ligaments and other diseases in horses without a long convalescent period.
NUCLEAR MAGNETIC RESONANCE TREATMENT (MBST®) OF CLINICAL SYMPTOMS CAUSED BY OSTEOARTHRITIS: DOUBLE-BLINDED PLACEBO-CONTROL STUDY IN DOGS
3) osteoporosis market
Today pharma at best is 20% effective for bone growth, MBST Treatments over 80 percent. The point to make pharma will never be effective for curing osteoporosis.
Osteoporosis Drugs Market Size To Reach $16.3 Billion By 2025
The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel sign "inform consent" before they will be enrolled in the study. The best for making a reliable conclusion regarding the therapeutic effect of MBST or any other treatment modalities, is a study done as a double-blind, randomized, prospective trial. The problem related to the skeleton diseases is that there is no any method able to measure the quality of cartilage or bone strength, which is the most important in the evaluation of the therapeutic effect.
This more validates the technology that most human cell tissue can be rejuvenated back to normal state that was “damage.”
COSMETIC/ DERMATOLOGY MARKET
A “Cure” for Male Pattern Baldness
We have the study from Dr. Eckart Voss and he says in his study that the hair density improvements are significant. There was no test person with complete baldness except 1 test person had almost baldness, as there were just 12 hairs before the treatment and 30 hairs 16 weeks after treatment. Area: 1 square centimeter.
Womens hair growth is actually larger market and be more effective as need live tissue , meaning early stages roughly first years 1- 5 . Dead cells will not work .
Rejuvenate cell tissue grow this effects over 100 million people A basic clinical study that show promise organ tissue that cells will grow.
The Future of Diabetes Treatment: Is a Cure Possible? Best Hope Is Cell Therapy
MedTec is looking for a partner.
Urology - Erectile Dysfunction
Neotone Germany company that makes electronic stimulation for ED and FDA approved. This can be incorporated into “universal medical device" Now under agreement with JLM
MBST Treatments has no clinical studies but electronic stimulation technologies are providing proof as a better alternative then pharma.
Nexstim Germany GmbH
Lyoner Str. 1460528 Frankfurt Germany makes brain mapping and is FDA approved
Early stages to partner and start clinical studies on addressing treatments for depression
Digital Therapeutics the "Digital Therapeutics Market 2014 - 2025" report to their offering. The global digital therapeutics market is expected to reach USD 9.3 billion by 2025.
Digital therapeutics, known as software-as-a-drug, has undergone significant developments, because of its cost-effectiveness and the potential to influence human behavior - a challenge that is difficult to overcome in healthcare. MBST Treatments has 20 different variable frequencies. An example osteoporosis for bone growth uses only one selected frequency which is program in the chip cards. A medical that cures arthritis and an alternative treatment that having knees or hip implants , an 80 % + effective for osteoporosis versus pharma today is at best 20% just these three areas is over $100 billion a year . If you can perfect liver cell growth , diabetes two , neuroscience - depression, dermatology ( hair growth ), audiology ( correct cilia for hearing lost ) then upwards to half trillion.
Biophysical stimulation is disruptive and needs an outsider to validated the technology.
companies under agreement continue:
Next Wave Ltd
Brännbackantie 8 FIN-10120 Tähtelä Finland www.nextwaveworldwide.com
Physioacoustic therapy affects all body functions, mainly the control center in the brains, the thalamus, but also on other nerve tissue, muscle and connective tissue and the blood and lymph circulation. The technology has been incorporated into a special reclining therapy chair and into a luxurious wellnessbed. Here are six audio speakers placed connected to a special software program. The speakers produce audible and sensible sound vibrations that will influence the body at cellular level.
Physioacoustic therapy is based on the natural frequency of every human cell. When playing the correct frequency a specific group of cells will vibrate unconstrained. In physics this is called resonance. The natural frequencies of numerous groups of body cells are stored in the computer software. Different frequencies in a range of 27 till 113 Hertz, are combined to achieve the optimum resonance. The unique ability to control the direction of the sound – from bottom to top, and vice versa – will stimulate the blood and lymph circulation. Changing the strength (pulsation) of the sound vibrations will prevent overstimulation.
Physioacoustic therapy works through clothing, bandage, medical support modifications or plaster cast.
Physiocoustic therapy is also called: Physio Acoustic, PAS, PA or Sound Wave therapy.
Physioacoustic Therapy equipments has been sold over 2000 units around the
WorldWhen launched in Scandinavia several years ago, Next Wave® quickly became
a leader in the Complementary and Alternative device marketplace, providing full body
sound stimulation treatment for patients of medical professionals, senior living facilities,
autism treatment centers,hospitals, drug rehabilitation facilities, and sports medicine.
The device has been used in other parts of the world to safely and successfully treat a wide range of
conditions, including the following:
Post-traumatic stress disorder (PTSD)
Multiple sclerosis (MS)
And dementia and ALS
The FDA clearing for Parkinson's, dementia, osteoporosis and Alzheimer's would be easier because Next Wave have some studies which show that the PA method is very effective for these symptoms above.
Effects of a low-frequency sound wave therapy program on functional capacity, blood circulation, and bone metabolism in frail old men and women.
DUALIS Med Tech GmbH
In collaboration with the German Aerospace Center (DLR) Am Technologiepark 8+1082229 Seefeld, Germany
Technology: Wireless transfer energy to recharge implantable devices
Markets: Implantable devices OEMS
DUALIS wireless technology uses the principle of inductive coupling which makes it possible to wirelessly transfer energy to a wide variety of electronic devices. This makes the transfer of energy incredibly efficient and reliable, and does not require direct user interface with the energy source. The modular construction makes it possible to adapt and integrate the technology for a wide range of uses. In addition to the supply of energy, DUALIS offers the possibility of parallel data transfer. To do this, various safe RF communication technologies are used, depending on the intended purpose.
JLM client Dualis brings in ReliantHeart
Dualis MedTech and ReliantHeart Partner on Fully Implantable TET System for the HeartAssist5® LVAD
ReliantHeart, Inc., an innovative supplier of advanced mechanical circulatory assist technologies, and Dualis MedTech GmbH, a provider of wireless energy and charging technology, have joined together to implement a wireless, Transcutaneous Energy Transfer system (TET) exclusively for the HeartAssist5® Ventricular Assist Device.
Dualis has agreed to integrate its wireless energy transfer technology MedBase® with the HeartAssist5® VAD. ReliantHeart’s novel HeartAssist5® (HA5) is the most energy efficient LVAD available.
In its new configuration, the HA5 will draw less than half of the energy of any other full flow LVAD. ReliantHeart refers to this energy efficient pump as being Forward Compatible with future product introduction, including the wireless Transcutaneous Energy Transfer system (TET).
Dualis is an integral part of a Forward Compatibility team formed by ReliantHeart to cooperate on an assembly of technologies intended to reduce adverse events associated with LVADs. The team includes several other companies: Lynium, Kollmorgen, Device Solutions, Transonic, Revel Engineering, Numerex, Cathtek, and Yarborough Electronics.
Several months of collaboration culminated in Houston last month, where engineers and product managers from these companies shared a behind-the-scenes tour of the Johnson Space Center, an appropriate setting for both Dualis and ReliantHeart whose roots stem from the aerospace industry. Dualis was formed from the German Centre for Aeronautics and Aerospace, and now implements its technologies for the medical device industry. ReliantHeart’s ventricular pump was developed with NASA technology and was awarded the NASA Invention of the Year.
According to ReliantHeart CEO Rodger Ford; “Dualis is heads and shoulders above most similar teams of its kind. Our partnership is more than just collaboration, it is a crusade to reduce adverse events in the LVAD field. Our mission is to compress time and accelerate beneficial outcomes. Artificial heart pumps need power but running wires through the skin leads to infection and patient discomfort. The solution is to invent a device to transfer power without wires.”
Dualis MedBase® technology will provide this solution by using magnetic coils to transfer power from outside to inside the body with no wires that penetrate the body. It sounds like science fiction, and yet will be available in 2016. Patients with a ReliantHeart HA5 will be able to upgrade to the wireless system without exchanging the pump, thereby eliminating driveline infection. “Patients will be able to enjoy the physical and social activities that are limitless without a wire,” Ford said.
Dualis MedTech GmbH started research and development of the MedBase® technology in 2006 and has since gained a substantial lead in wireless power technology, and conducted successful animal trials. Stephan Sagolla, CEO of Dualis indicated, “The internal coil is about two inches in diameter and will communicate with an internal battery and power management much like a pacemaker system. The patient will be wireless.”
ReliantHeart, Inc. is an innovative supplier of advanced mechanical circulatory assist technologies that are changing the approach to the treatment of advanced heart failure. It develops and manufactures the HeartAssist5® Ventricular Assist Device. ReliantHeart’s roots are in Houston, Texas, where it has been generously influenced by the transplant centers of Texas Heart, Methodist DeBakey and Memorial Hermann, and its technology originally inspired by NASA, the Johnson Space Center and Baylor School of Medicine.
Dualis MedTech GmbH is an innovative development service provider which supports its customers from the idea stage right through to the certification of tailor-made systems and products. As a spin-off of the Deutsches Zentrum für Luft- und Raumfahrt (DLR e. V., German Centre for Aeronautics and Aerospace), the company has transferred technology used in aeronautics and applied it to medical technology and also provide services to other sectors such as the automotive supply industry, consumer electronics and machine and plant construction.
Dualis offers manufacturers of medical devices and active implants a fully comprehensive service package for the production, integration and adjustment of MedBase® to their proprietary products. Dualis complies with the extremely demanding regulatory requirements for medical devices.
STABILO International GmbH Head office Schwanweg 1 - 90562 Heroldsberg Germany
Stabilo Digipen As Diagnostic Tool To Assessment Hand Surgery Feedback Instantly , Also Early Detection of Dementia ( Digital pen is better dementia-prediction tool than a doctor stated MIT News ).
A new study for hand injuries for detection of improvement simply use by patients at pre and post surgery. What Stabilo provides is an objective measurement to detect weaknesses in hand motion and track progress during therapy. We also provide a software which guides the therapist through a standardized test and automatically compiles a report. Digipen was first developed for the educational and therapeutical markets. Today we use it for the measurement of handwriting skills. An occupational therapy application would need no special development and can be implemented out of the box. Our current handwriting application for occupational therapists is written on Xamarin which allows it to be run on iOS, Android or Windows. An Android toolkit is available for easy integration into Android apps. An iOS toolkit is under development.
The Digipen is not meant for pointing at a screen, but for writing on paper. We want on purpose to do away with special paper or special tablet surfaces which can locate the pen tip. Instead, we measure relative position data (relative to the position before, that is) as opposed to the absolute position data of Anoto pens or digitizer tablets. We expect that a typical application of our pen would be as an ergonomic mouse with proportional input. While a mouse is on/off only when you click a button, we can transmit proportional data via pen pressure. The motion sensors pick up the movement, and the tilt or rotation angles of the pen allow to convey further information. This makes our pen suitable as a low-cost replacement for a graphical tablet, without the bulky tablet.
The STABILO Digipen has these characteristics:
• Writes on paper with a minimum writing length of 1200 m.
• Transmits acceleration, rotation, attitude and tip motion data during use when connected to a compatible wireless device.
• Storage of acceleration, rotation, attitude and tip motion data internally for at least 25 minutes when the connection is lost.
• A high data rate wired connection to enable the download of stored data and the update of the internal firmware.
• A rechargeable, internal power source which keeps it powered for at least 20 hours.
We like to discuss Digipen writing motion assessment technology as a first starting point. For a video conference, point your browser at https://appear.in/digistift.
Treating people with hand injuries in general, the pen should easily be able to measure restrictions in the movement of finger joints, especially those of the thumb and the index finger. .Stabilo develops a diagnostic device as a “ tool “ for doctors patients as provide real feedback from surgery. Second area is clinical test demonstrates how people perform when it comes to verbal understanding, memory, and spatial knowledge, and is used to detect Parkinson's and Alzheimer’s.
The target market orthopedic lower extremity (hand surgeons), neurologist , general pratitioners and arthritis- pharma as clinical trial diagnostic tool.
Biozoom Services GmbH Wilhelmshöher Allee 273A D-34131 Kassel Germany
Biozoom is a developer of handheld diagnostic spectrometry systems, which analyzes biomarkers in skin that are decisive for control and improvement of a healthy lifestyle.
A well-being technology that is used as a diagnostic tool. The Company's transdermal scanner measures biomarkers, giving users the information they need to take control of their wellbeing. The biozoom scanner detects biomarkers by radiating light into the skin of the user's palm using light emitting diode (LED), and guiding back reflected light to a spectroscopic system developed.for number of applications. The biozoom antioxidant scanner uses Multiple Spatially Resolved Reflection Spectroscopy (MSRRS) to precisely measure the antioxidant level. The used LED light is safe and absolutely pain free.
Biozoom monitors your nutrition and tells you whether you have enough vitamins inside your body thus a sales enhancement tool to promote and explain premium products.
The target market is OEM general practitioners, pharmacy mini-clinics, nutrition vitamins and organ grocery retailers.
Likvor AB Tvistevägen 47a SE-90729UMEÅ, Sweden
Likvor (Medtech) Unique tools for assessing cerebrospinal fluid dynamics Why? Normal Pressure Hydrocephalus (NPH) is a treatable syndrome caused by disturbances in the circulation of cerebrospinal fluid (CSF). The symptoms are often misdiagnosed and mistreated as one of the dementia related diseases, such as Alzheimer’s and Parkinson’s.
How? Likvor’s CELDA® Instrument provides a solution to the pressing need for accurate differential diagnosis of aging related and other CSF dynamics related neurological conditions.
The best starting point is our website. www.likvor.com
One film about the product/NPH/symptoms: http://likvor.com/patients-0
A more “thorough” film about the CELDA System: http://likvor.com/movie-1
About Likvor and Patents: http://likvor.com/about-likvor
Successful: Testimonials: http://likvor.com/testimonials
Helpful info at YouTube: Here is a link to “The Untold Story” at 60-Minutes: ( This is Codman shunt used by the patient ) https://www.youtube.com/watch?v=fm0CZh_X-vM
A video from year 2013: “Normal Pressure Hydrocephalus: NPH From Diagnosis To Treatment” (Explains also the procedure from the neurologist to the neurosurgeon. Right in between – you would find Likvor CELDA® System! And you do not need to perform the tap test as it is included in the CELDA® as well) https://www.youtube.com/watch?v=YdxeWPiT3fA
Likvor CELDA® System works extremely well both preoperatively when diagnosing the NPH patient and postoperatively when optimizing the shunt settings and/or testing the shunt functionality.
Likvor AB is present in five countries in Europe and like to hand off the technology (license) to medical OEM DBS
(PUBL) PO BOX 11151 SE-161 SWEDEN
Diagnostics cancer (bladder) with UBC Rapid POS device for instant read (less than 15 minutes) with better sensitivity at significantly lower cost. Urine sample administrated thus a very simple process. Other cancer diagnostic (breast, lung, prostate) are only available as Elisa or Irma.
Cystoscopy is the mainstay for the diagnosis of bladder cancer
UBC® Rapid demonstrates high diagnostic sensitivity in particular for CIS(Cancer In Situ) and high-risk bladder cancer patients
Benign conditions of the urinary tract must be considered when evaluate data as they may cause false positive reading, as for all urinary based tests.
UBC® Rapid is a quick assay and test result will be available at the patient visit
Quantitative UBC® Rapid measures a continuous parameter â€“ suitable for risk stratification
Lyme disease detection see MoncTotal Deck
Countries like Germany in less than two and half years have captured over 50% market share of 500,000 diagnostics reads a year. IDL would like to handoff and provide exclusive global license / private label rights to medical manufacturer with a sales channel of 50+ countries.